TSRO - Tesaro, Inc.
| Previous Close | 123.00 |
| Open | 124.00 |
| Bid | 80.00 x 200 |
| Ask | 0.00 x 0 |
| Day's Range | 120.12 - 124.71 |
| 52 Week Range | 106.64 - 192.94 |
| Volume | 489,755 |
| Avg. Volume | 879,978 |
| Market Cap | 6.52B |
| Beta | 2.20 |
| PE Ratio (TTM) | -12.09 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Capital Cube•4 days agoTESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : October 13, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for TESARO, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)
Markit•6 days agoSee what the IHS Markit Score report has to say about TESARO Inc.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. The net inflows of $2.53 billion over the last one-month into ETFs that hold TSRO are not among the highest of the last year and have been slowing.
- Zacks•12 days ago
Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock?
Investors in Tesaro (TSRO) need to pay close attention to the stock based on moves in the options market lately.
- Zacks•14 days ago
The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
- Capital Cube•15 days ago
TESARO, Inc. – Value Analysis (NASDAQ:TSRO) : October 2, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives TESARO, Inc. a score of 25. Our analysis is based on comparing TESARO, Inc. with the following peers – Clovis Oncology, Inc., ZIOPHARM Oncology, Inc., Amgen Inc., Dare Bioscience, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Insys Therapeutics, Inc. and Pfizer Inc. (CLVS-US, ZIOP-US, AMGN-US, DARE-US, ... Read more (Read more...)
Capital Cube•18 days agoTESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : September 29, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for TESARO, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)
Markit•20 days agoSee what the IHS Markit Score report has to say about TESARO Inc.
TESARO Inc NASDAQ/NGS:TSRO
- Zacks•25 days ago
Cancer Space Update: Mixed Week for Pfizer, Roche Falters
Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.
- Zacks•27 days ago
Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.
- Zacks•29 days ago
TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion
TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.
- Capital Cube•last month
ETFs with exposure to TESARO, Inc. : September 12, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TESARO, Inc. Here are 5 ETFs with the largest exposure to TSRO-US. Comparing the performance and risk of TESARO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Markit•last monthSee what the IHS Markit Score report has to say about TESARO Inc.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $1.56 billion over the last one-month.
- Capital Cube•2 months ago
TESARO, Inc. breached its 50 day moving average in a Bullish Manner : TSRO-US : September 1, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for TESARO, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)
- Capital Cube•2 months ago
ETFs with exposure to TESARO, Inc. : September 1, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TESARO, Inc. Here are 5 ETFs with the largest exposure to TSRO-US. Comparing the performance and risk of TESARO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Motley Fool•2 months ago
We Got It Wrong With OPKO Health -- Now What?
OPKO Health’s been dealt setbacks that have caused its shares to nose-dive, rather than head higher. Is that about to change?
Markit•2 months agoSee what the IHS Markit Score report has to say about TESARO Inc.
TESARO Inc NASDAQ/NGS:TSRO
Capital Cube•2 months agoTESARO, Inc. :TSRO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
Categories: Yahoo FinanceGet free summary analysis TESARO, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of TESARO, Inc. – Clovis Oncology, Inc., ZIOPHARM Oncology, Inc., Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Insys Therapeutics, Inc. and Pfizer Inc. (CLVS-US, ZIOP-US, AMGN-US, MRK-US, BMY-US, ... Read more (Read more...)
- Barrons.com•2 months ago
Tesaro: Losing Its Edge?
The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.
- Barrons.com•2 months ago
Ovarian Cancer Market Still Up For Grabs
The Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients. Morgan Stanley’s Andrew Berens and his team are updating their models following the news, writing that he expects the three major players—AstraZeneca, Clovis Oncology (CLVS), and Tesaro (TSRO)—will likely split the market for second line (2L) treatment.
Markit•2 months agoSee what the IHS Markit Score report has to say about TESARO Inc.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $1.34 billion over the last one-month.
Markit•2 months agoSee what the IHS Markit Score report has to say about TESARO Inc.
TESARO Inc NASDAQ/NGS:TSRO
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of TSRO earnings conference call or presentation 8-Aug-17 8:15pm GMT
Q2 2017 TESARO Inc Earnings Call
- Barrons.com•2 months ago
Biotech: Why Clovis And Tesaro Look Well Positioned
Morgan Stanley's Andrew Berens and his team have a note out on biotech, writing that investors should buy Clovis Oncology (CLVS) and Tesaro (TSRO) ahead of any labeling decision by the Food and Drug Administration for AstraZeneca's (AZN) Lynparza breast cancer drug. Berens writes that he expects the most likely outcome is that the FDA will limit the label BRCA patients--or at least have less promising results outside BRCA.
- Associated Press•2 months ago
Tesaro reports 2Q loss
The Waltham, Massachusetts-based company said it had a loss of $2.82 per share. The results did not meet Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research ...
- Benzinga•2 months ago
A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision
Morgan Stanley said in a note Tuesday it would be buyers of Clovis Oncology Inc (NASDAQ: CLVS ) and TESARO Inc (NASDAQ: TSRO ) ahead of the Lynparza label decision. AstraZeneca plc (ADR) (NYSE: AZN )'s ...
